A 58-year-old male with type 2 diabetes, hypertension, and hyperlipidemia presents for a follow-up. His current medications include metformin, lisinopril, and atorvastatin. His A1C is 7.8% and his blood pressure is 138/86 mmHg. He reports occasional postprandial heartburn. When considering an additional medication to improve his glycemic control, which of the following would be most appropriate, given his cardiovascular risk factors and current symptoms?
- ASitagliptin
- BEmpagliflozin
- CGlipizide
- DPioglitazone
Show answer & explanationAnswer & explanation
Correct answer: B. Empagliflozin
Empagliflozin is an SGLT2 inhibitor. It is strongly recommended for type 2 diabetes patients with established cardiovascular disease or at high risk (like this patient with HTN, hyperlipidemia, and diabetes), due to its proven cardiovascular and renal benefits, in addition to glucose lowering. It also promotes weight loss and can modestly lower blood pressure. Glipizide can cause hypoglycemia and weight gain. Sitagliptin is weight-neutral but lacks the robust CV benefits of SGLT2 inhibitors. Pioglitazone can worsen heart failure and cause weight gain.
Why the other options are wrong
- A. Sitagliptin (DPP-4 inhibitor) is weight-neutral and has a low hypoglycemia risk, but it does not offer the same robust cardiovascular protection as SGLT2 inhibitors for patients with established CV risk.
- C. Glipizide (sulfonylurea) carries a high risk of hypoglycemia and weight gain, which are undesirable in this patient.
- D. Pioglitazone (TZD) can cause weight gain and fluid retention, potentially exacerbating heart failure, and its cardiovascular benefits are less clear and have specific contraindications.
DM2 Medication Selection with ASCVD/Risk
For patients with type 2 diabetes and established atherosclerotic cardiovascular disease (ASCVD) or high cardiovascular risk, SGLT2 inhibitors (like empagliflozin) or GLP-1 receptor agonists are preferred agents due to their proven cardiovascular and renal protective benefits, independent of glycemic control.
- SGLT2 inhibitors and GLP-1 RAs have ASCVD benefits.
- Consider patient-specific comorbidities and medication side effects.
- Avoid medications that worsen CV risk (e.g., fluid retention with TZDs).
Memory trick: Diabetes Heart Smart? SGLT2 is the start!